US 12310956
Topical roflumilast formulation having improved delivery and plasma half-life
granted A61KA61K31/44A61K45/06
Quick answer
US patent 12310956 (Topical roflumilast formulation having improved delivery and plasma half-life) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ARCUTIS BIOTHERAPEUTICS, INC.
- Grant date
- Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K31/44, A61K45/06, A61K47/06, A61K47/10